{
    "2019-08-23": [
        [
            {
                "time": "",
                "orginal_text": "天坛生物（600161）：销售端拓展力度加大，业绩略超预期【中报点评|西南医药朱国广陈铁林团队】",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "销售端",
                        "业绩",
                        "超预期"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "天坛生物：血制品行业龙头，长期增长前景确定，维持增持评级",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "血制品",
                        "行业龙头",
                        "增长前景",
                        "增持"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "orginal_text": "【国信医药|半年报点评】天坛生物：业绩高增长，现金流充沛",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "业绩",
                        "高增长",
                        "现金流"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "天坛生物2019年中报点评:业绩高增长,现金流充沛",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "2019年",
                        "中报",
                        "业绩",
                        "高增长",
                        "现金流"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}